COM Share Price

Open 3.69 Change Price %
High 3.80 1 Day 0.03 0.80
Low 3.69 1 Week 0.20 5.56
Close 3.80 1 Month -0.10 -2.56
Volume 23365 1 Year -8.30 -68.60
52 Week High 11.35
52 Week Low 3.25
COM Important Levels
Resistance 2 3.90
Resistance 1 3.86
Pivot 3.76
Support 1 3.74
Support 2 3.70
TSE Canada Most Active Stocks
BIN 41.40 -1.62%
BIN 41.40 -1.62%
LSG 2.08 8.33%
LSG 2.08 8.33%
LSG 2.08 8.33%
TBE 0.03 0.00%
MFC 24.30 2.57%
MFC 24.30 2.57%
MFC 24.30 2.57%
MFC 24.30 2.57%
More..
TSE Canada Top Gainers Stocks
TVI 0.02 100.00%
ST 0.02 100.00%
ST 0.02 100.00%
CUR 0.02 100.00%
CUR 0.02 100.00%
CUR 0.02 100.00%
TPL 0.02 100.00%
TPL 0.02 100.00%
QEC 0.74 42.31%
QEC 0.74 42.31%
More..
TSE Canada Top Losers Stocks
GBV 0.46 -24.59%
HE 0.04 -20.00%
HE 0.04 -20.00%
HBP 1.35 -12.90%
HBP 1.35 -12.90%
NKO 0.08 -11.11%
NKO 0.08 -11.11%
NKO 0.08 -11.11%
CCM 0.08 -11.11%
CCM 0.08 -11.11%
More..

Cardiome Pharma Corporation (TSE: COM)

COM Technical Analysis 4
As on 8th Dec 2016 COM Share Price closed @ 3.80 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 5.60 & Sell for SHORT-TERM with Stoploss of 3.88 we also expect STOCK to react on Following IMPORTANT LEVELS.
COM Target for December
1st Target up-side 4.01
2nd Target up-side 4.34
3rd Target up-side 4.66
1st Target down-side 3.09
2nd Target down-side 2.76
3rd Target down-side 2.44
COM Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.cardiome.com
COM Address
COM
6190 Agronomy Road
Suite 405
Vancouver, BC V6T 1Z3
Canada
Phone: 604-677-6905
Fax: 604-677-6915
Interactive Technical Analysis Chart Cardiome Pharma Corporation ( COM TSE Canada )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Cardiome Pharma Corporation
COM Business Profile
Cardiome Pharma Corp., a biopharmaceutical company, is engaged in the development and commercialization of cardiovascular therapies that enhance the life and health of patients. It offers BRINAVESS (vernakalant IV), for conversion of recent onset atrial fibrillation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in acute coronary syndrome patients. The company’s pre-clinical research and development focuses on modulating cellular proteins (ion channels) that gate the movement of ions across the cell membrane to control various functions, including contraction of muscles, secretion from glands, and responses to foreign bodies and inflammation. It has operations in Canada, the United States, Switzerland, and the United Kingdom. The company was formerly known as Nortran Pharmaceuticals Inc. and changed its name to Cardiome Pharma Corp. in June 2001. Cardiome Pharma Corp. was founded in 1986 and is headquartered in Vancouver, Canada.